Search

Your search keyword '"Byung-Jae Lee, MD, PhD"' showing total 2 results
Start Over Author "Byung-Jae Lee, MD, PhD" Topic biologics
2 results on '"Byung-Jae Lee, MD, PhD"'

1. Effect of biologic therapies on quality of life in severe asthma: Findings from the PRISM study

Author

Hyo-In Rhyou, MD, PhD, Hyun-Kyoung Kim, MPH, Woo-Jung Song, MD, PhD, Sang Min Lee, MD, PhD, Sang-Ha Kim, MD, PhD, Jae-Woo Kwon, MD, PhD, Han-Ki Park, MD, PhD, Hye-Kyung Park, MD, PhD, Sang Hoon Kim, MD, PhD, Jeong-Hee Choi, MD, PhD, Sujeong Kim, MD, PhD, So-Young Park, MD, PhD, Sae-Hoon Kim, MD, PhD, Ji-Yong Moon, MD, PhD, Jae-Woo Jung, MD, PhD, Young-Joo Cho, MD, PhD, Chan Sun Park, MD, PhD, Byung Keun Kim, MD, PhD, Joo-Hee Kim, MD, PhD, Min-Suk Yang, MD, PhD, Min-Hye Kim, MD, PhD, Young-Hee Nam, MD, PhD, Taehoon Lee, MD, PhD, Byung-Jae Lee, MD, PhD, Pankaj Bhavsar, PhD, Ian M. Adcock, PhD, Kian Fan Chung, MD, DSc, and Tae-Bum Kim, MD, PhD

Subjects
Severe asthma, Quality of life, Biologics, Anti-IL-5, Anti-IL-4/IL-13, Immunologic diseases. Allergy, RC581-607
Abstract

Background: Anti-type 2 (T2) biologic therapies (biologics) improve exacerbation rates, lung function, and asthma-related quality of life (QoL) in patients with severe T2 asthma. However, studies comparing different biologics are lacking. We evaluated the QoL in patients with severe asthma comprehensively and compare the efficacy of different T2-directed biologics using QoL questionnaires. Methods: We compared the QoL between severe and mild-to-moderate asthma and between severe asthma with and without biologics treatment. Data of mild-to-moderate were extracted from the Cohort for Reality and Evolution of Adult Asthma in Korea, and data of severe asthma were collected from the Precision Medicine Intervention in Severe Asthma. We included 183 patients with severe asthma treated with T2 biologics or conventional therapy between April 2020 and May 2021 and assessed QoL of them using the Questionnaire for Adult Korean Asthmatics (QLQAKA), Severe Asthma Questionnaire (SAQ), and EuroQoL-5Dimensions (EQ-5D) at baseline and 6 months. Results: The EQ-5D index (0.803) of severe asthma was lower than that of other chronic diseases representing a worse QoL. The scores for all questions of QLQAKA, except “cough,” were lower (less control) in the severe asthma group than in the mild-to-moderate asthma group at baseline and 6 months (P 0.05). Conclusion: QoL was worse in severe asthma than in mild-to-moderate asthma and other chronic diseases. T2 biologics equally improved QoL in patients with severe asthma.

Published
2024
Full Text
View/download PDF

2. A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: Findings from the PRISM study

Author

Ji-Su Shim, MD, PhD, Hyunkyoung Kim, MS, Jae-Woo Kwon, MD, PhD, So-Young Park, MD, PhD, Sujeong Kim, MD, PhD, Byung-Keun Kim, MD, PhD, Young-Hee Nam, MD, PhD, Min-Suk Yang, MD, PhD, Mi-Yeong Kim, MD, PhD, Sae-Hoon Kim, MD, PhD, Byung-Jae Lee, MD, PhD, Taehoon Lee, MD, PhD, Sang-Ha Kim, MD, PhD, So Young Park, MD, PhD, Young-Joo Cho, MD, PhD, Chan Sun Park, MD, PhD, Jae-Woo Jung, MD, PhD, Han-Ki Park, MD, PhD, Joo-Hee Kim, MD, PhD, Jeong-Hee Choi, MD, PhD, Ji-Yong Moon, MD, PhD, Ian Adcock, MD, PhD, Kian Fan Chung, MD, PhD, Min-Hye Kim, MD, PhD, and Tae-Bum Kim, MD, PhD

Subjects
Asthma-COPD overlap, Asthma, Biologics, Monoclonal antibodies, Treatment response, Immunologic diseases. Allergy, RC581-607
Abstract

Background: Despite the increasing use of biologics in severe asthma, there is limited research on their use in asthma-chronic obstructive pulmonary disease overlap (ACO). We compared real-world treatment responses to biologics in ACO and asthma. Methods: We conducted a multicenter, retrospective, cohort study using data from the Precision Medicine Intervention in Severe Asthma (PRISM). ACO was defined as post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) 10 pack-years. Physicians selected biologics (omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab) based on each United States Food & Drug Administration (FDA) approval criteria. Results: After six-month treatment with biologics, both patients with ACO (N = 13) and asthma (N = 81) showed positive responses in FEV1 (10.69 ± 17.17 vs. 11.25 ± 12.87 %, P = 0.652), Asthma Control Test score (3.33 ± 5.47 vs. 5.39 ± 5.42, P = 0.290), oral corticosteroid use (−117.50 ± 94.38 vs. −115.06 ± 456.85 mg, P = 0.688), fractional exhaled nitric oxide levels (−18.62 ± 24.68 vs. −14.66 ± 45.35 ppb, P = 0.415), sputum eosinophils (−3.40 ± 10.60 vs. −14.48 ± 24.01 %, P = 0.065), blood eosinophils (−36.47 ± 517.02 vs. −363.22 ± 1294.59, P = 0.013), and exacerbation frequency (−3.07 ± 4.42 vs. −3.19 ± 5.11, P = 0.943). The odds ratio for exacerbation and time-to-first exacerbation showed no significant difference after full adjustments, and subgroup analysis according to biologic type was also showed similar results. Conclusions: Biologics treatment response patterns in patients with ACO and asthma were comparable, suggesting that biologics should be actively considered for ACO patients as well.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results